MiR‑599 serves a suppressive role in anaplastic thyroid cancer by activating the T‑cell intracellular antigen
- Jian Wei Bi
- Yan Liang Zou
- Jian Tong Qian
- Wen Bin Chen
Published online on: August 7, 2019
Copyright: © Bi et al.
This is an open access article distributed under the terms of Creative Commons Attribution License.
| PMC Statistics:
Total PDF Downloads:
| PMC Statistics:
Anaplastic thyroid cancer (ATC) has a mean survival time of 6 months and accounts for 1‑2% of all thyroid tumors. Understanding the underlying molecular mechanisms of carcinogenesis and progression in ATC would contribute to the identification of novel therapeutic targets. A previous study revealed that microRNA (miR)‑599 was associated with tumor initiation and development in certain types of cancer. However, the specific functions and mechanisms of miR‑599 in ATC are poorly understood. The objective of the present study was to identify its expression, function and molecular mechanism in ATC. The expression levels of miR‑599 in 10 pairs of surgical specimens and human ATC cell lines were examined by reverse transcription‑quantitative polymerase chain reaction. Function assays illustrated that miR‑599 overexpression not only suppressed KAT‑18 cell viability, proliferation and metastasis in vitro and decreased tumor growth in the tumor xenograft model but also induced cell apoptosis. Furthermore, T‑cell intracellular antigen (TIA1), a tumor suppressor, was confirmed as a direct target of miR‑599. It was demonstrated that TIA1 silencing rescued the inhibitory effect of migration and invasion induced by the overexpression of miR‑599 in KAT‑18 cells. In conclusion, the present study revealed that miR‑599 inhibited ATC cell growth and metastasis via activation of TIA1. Therefore miR‑599 may be a novel molecular therapeutic target for ATC.